The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
- Authors: Gratsianskaya S.E.1, Valieva Z.S.1, Martynyuk T.V.1,2
-
Affiliations:
- Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology
- Pirogov Russian National Research Medical University
- Issue: Vol 92, No 9 (2020)
- Pages: 77-84
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/46859
- DOI: https://doi.org/10.26442/00403660.2020.09.000717
- ID: 46859
Cite item
Full Text
Abstract
Currently, treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is focused on three signaling pathways: the NO pathway, the endothelin pathway, and the prostacyclin pathway. Riociguat is the only representative of stimulators of the soluble guanylate cyclase (sGC) class that is approved for the treatment of PAH and inoperable and persistent/recurrent CTEPH. The review presents data from clinical trials showing a positive effect of riociguat on the functional and hemodynamic profile of patients with PAH and CTEPH. In recent years there has been much discussion about the possibility of optimizing therapy by switching to drugs that affect a single pathogenesis target. Thus, sGC stimulants have obvious advantages over phosphodiesterase type 5 (PDE-5) inhibitors, including the ability of riociguat to exert pharmacological effects (due to a NO-independent mechanism of action) even in conditions of reduced NO production. Switching from PDE-5 to riociguat may be safe and appropriate, according to clinical trials presented in the review. In accordance with the guidelines for the diagnosis and treatment of pulmonary hypertension of the Eurasian Association of cardiologists from 2019, this strategy is approved when PDE5 therapy is ineffective in patients with PAH FC III (WHO).
Full Text
##article.viewOnOriginalSite##About the authors
S. E. Gratsianskaya
Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology
Author for correspondence.
Email: s.gratsianskaya@gmail.com
лаборант-исследователь отд. легочной гипертензии и заболеваний сердца ИКК им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowZ. S. Valieva
Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology
Email: s.gratsianskaya@gmail.com
ORCID iD: 0000-0002-9041-3604
к.м.н., н.с. отд. легочной гипертензии и заболеваний сердца ИКК им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowT. V. Martynyuk
Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology; Pirogov Russian National Research Medical University
Email: s.gratsianskaya@gmail.com
ORCID iD: 0000-0002-9022-8097
д.м.н., рук. отд. легочной гипертензии и заболеваний сердца ИКК им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии», проф. каф. кардиологии ФДПО ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»
Russian Federation, MoscowReferences
- Мартынюк Т.В. Легочная гипертензия: диагностика и лечение. М.: Медицинское информационное агентство, 2018 [Martynyuk TV. Pulmonary hypertension: diagnostics and treatment. Moscow: Medical informational agency. 2018 (In Russ.)].
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(Suppl.25):D34-41. doi: 10.1016/j.jacc.2013.10.029
- Чазова И.Е., Мартынюк Т.В., Валиева З.С. и др. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал. 2020;1:78-122 [Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian Heart Journal. 2020;1:78-122 (In Russ.)]. doi: 10.24411/2076-4766-2020-10002
- McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-94. doi: 10.1161/CIRCULATIONAHA
- Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi: 10.1183/13993003.01032-2015
- Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther. 2014;141(2):172-91. doi: 10.1016/j.pharmthera.2013.10.002
- Schermuly RT, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008;32:881-91. doi: 10.1183/09031936.00114407
- Мартынюк Т.В. Ингаляционный оксид азота, ингибиторы фосфодиэстеразы типа 5, стимуляторы гуанилатциклазы. В кн.: Легочная гипертензия. Под ред. И.Е. Чазовой, Т.В. Мартынюк. М.: Практика, 2015; с. 766-810 [Martynyuk TV. Inhaled nitric oxide, phosphodiesterase type 5 inhibitors, guanylate cyclase stimulants. Book: Pulmonary hypertension. In: Chazova IE, Martynyuk TV. Moscow: Praktika, 2015; p. 766-810 (In Russ.)].
- Galiè N, Ghofrani HA, Torbicki А, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57.
- Валиева З.С., Таран И.Н., Мартынюк Т.В., Чазова И.Е. Современный взгляд на место риоцигуата в лечении легочной гипертензии. Терапевтический архив. 2018;90(4):55-9 [Valieva ZS, Taran IN, Martynyuk TV, Chazova IYe. Modern view on the place of riociguat in the treatment of pulmonary hypertension. Therapeutic Archive. 2018;90(4):55-9 (In Russ.)]. doi: 10.26442/terarkh201890455-59
- Brown Т. FDA Panel Recommends Riociguat (Adempas) for 2 Pulmonary Hypertension Indications. 2013. https://www.medscape.com/viewarticle/809083
- Инструкция по медицинскому применению препарата Адемпас. Регистрационный номер: ЛП-002639 (версия от 10.10.2019). Государственный реестр лекарственных средств [Instructions for the medical use of the drug Adempas. Registration number: ЛП-002639 (version dated 10.10.2019). State Register of Medicines (In Russ.)]. https://grls.rosminzdrav.ru
- Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40. doi: 10.1056/NEJMoa1209655
- Rubin LJ, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45:1303-13. doi: 10.1183/09031936.00090614
- Ghofrani HF, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open label, randomised, long-term extension trial. Lancet Respir Med. 2016;4(5):361-71. doi: 10.1016/S2213-2600(16)30019-4
- Rosenkranz S, Ghofrani HA, Beghetti M, et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015;101(22):1792-9. doi: 10.1136/heartjnl-2015-307832
- Sood N, Aranda A, Platt D, et al. Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study. Pulm Circ. 2019;9(1):2045894018823715. doi: 10.1177/2045894018823715
- Jungmann NA, Lang D, Saleh S, et al. In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1substrate riociguat. Expert Opin Drug Metab Toxicol. 2019;15(11):975-84. doi: 10.1080/17425255.2019.1681968
- Ghofrani HA, et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med. 2013;369:319-29. doi: 10.1056/NEJMoa1209657
- Simonneau G, D’Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45(5):1293-302. doi: 10.1183/09031936.00087114
- McLaughlin VV, Jansa P, Nielsen-Kudsk JE, et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulm Med. 2017;17(1):216. doi: 10.1186/s12890-017-0563-7
- Van Thor MCJ, Ten Klooster L, Snijder RJ, et al. Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension. Int J Cardiol Heart Vasc. 2019;22:163-8. doi: 10.1016/j.ijcha.2019.02.004
- Jansa P, Ambroz D, Kuchar J, et al. The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension – results of a retrospective clinical registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020. doi: 10.5507/bp.2019.061
- Tsai CH, Wu CK, Kuo PH, et al. Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Acta Cardiol Sin. 2020;36(1):64-71. doi: 10.6515/ACS.202001_36(1).20190612A
- Yamamoto K, Nishimura R, Kato F, et al. Protective role of endothelial progenitor cells stimulated by riociguat in chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2020;299:263-70. doi: 10.1016/ j.ijcard.2019.07.017
- Чазова И.Е., Валиева З.С., Наконечников С.Н. и др. Сравнительный анализ клинического, функционального, гемодинамического профиля пациентов с неоперабельной хронической тромбоэмболической и идиопатической легочной гипертензией по данным Российского регистра. Терапевтический архив. 2018;90(10): 63-73 [Chazova IE, Valieva ZS, Nakonechnikov SN, et al. Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry. Therapeutic Archive. 2018;90(10):63-73 (In Russ.)]. doi: 10.26442/00403660. 2019.09.000343
- Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53:1801889. doi: 10.1183/13993003.01889-2018
- Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50:1700889. doi: 10.1183/13993003.00889-2017
- Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50:1700740. doi: 10.1183/13993003.00740-2017
- Kylhammar D, Kjellstrom B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39:4175–81. doi: 10.1093/eurheartj/ehx257
- Humbert M, Farber HW, Ghofrani HA, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(6):1802004. doi: 10.1183/13993003.02004-2018
- Marra AM, Halank M, Benjamin N, et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res. 2018;19(1):258. doi: 10.1186/s12931-018-0957-y
- Leon-Velarde F, Maggiorini M, Reeves JT, et al. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol. 2005;6:147-57. doi: 10.1089/ham.2005.6.147
- Hoeper MM, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50(3):1602425. doi: 10.1183/13993003.02425-2016
- Gall H, Vachiéry JL, Tanabe N, et al. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. Lung. 2018;196:305-12. doi: 10.1007/s00408-018-0100-3
- Yamamoto K, Tanabe N, Suda R, et al. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor. Respir Investig. 2017;55(4):270-5. doi: 10.1016/j.resinv.2017.04.004
- Darocha S, Banaszkiewicz M, Pietrasik A, et al. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. Int J Cardiol. 2018;269:283-8. doi: 10.1016/j.ijcard.2018.07.015
- Kuroda K, Akagi S, Nakamura K, et al. Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study. Heart Lung Circ. 2020;29(3):331-6. doi: 10.1016/j.hlc.2019.01.013
- Taran IN, Belevskaya AA, Saidova MA, et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung. 2018;196(6):745-53. doi: 10.1007/s00408-018-0160-4
![](/img/style/loading.gif)